Development of a newborn screening follow-up algorithm for the diagnosis of isobutyryl-CoA dehydrogenase deficiency

Devin Oglesbee, Miao He, Nilanjana Majumder, Jerry Vockley, Ayesha Ahmad, Brad Angle, Barbara Burton, Joel Charrow, Regina Ensenauer, Can H. Ficicioglu, Laura Davis Keppen, Deborah Marsden, Silvia Tortorelli, Si Houn Hahn, Dietrich Matern

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

PURPOSE: Isobutyryl-CoA dehydrogenase deficiency is a defect in valine metabolism and was first reported in a child with cardiomyopathy, anemia, and secondary carnitine deficiency. We identified 13 isobutyryl-CoA dehydrogenase-deficient patients through newborn screening due to an elevation of C4-acylcarnitine in dried blood spots. Because C4-acylcarnitine represents both isobutyryl- and butyrylcarnitine, elevations are not specific for isobutyryl-CoA dehydrogenase deficiency but are also observed in short-chain acyl-CoA dehydrogenase deficiency. To delineate the correct diagnosis, we have developed a follow-up algorithm for abnormal C4-acylcarnitine newborn screening results based on the comparison of biomarkers for both conditions. METHODS: Fibroblast cultures were established from infants with C4-acylcarnitine elevations, and the analysis of in vitro acylcarnitine profiles provided confirmation of either isobutyryl-CoA dehydrogenase or short-chain acyl-CoA dehydrogenase deficiency. Isobutyryl-CoA dehydrogenase deficiency was further confirmed by molecular genetic analysis of the gene encoding isobutyryl-CoA dehydrogenase (ACAD8). Plasma acylcarnitines, urine acylglycines, organic acids, and urine acylcarnitine results were compared between isobutyryl-CoA dehydrogenase- and short-chain acyl-CoA dehydrogenase-deficient patients. RESULTS: Quantification of C4-acylcarnitine in plasma and urine as well as ethylmalonic acid in urine allows the differentiation of isobutyryl-CoA dehydrogenase-deficient from short-chain acyl-CoA dehydrogenase-deficient cases. In nine unrelated patients with isobutyryl-CoA dehydrogenase deficiency, 10 missense mutations were identified in ACAD8. To date, 10 of the 13 isobutyryl-CoA dehydrogenase-deficient patients remain asymptomatic, two were lost to follow-up, and one patient required frequent hospitalizations due to emesis and dehydration but is developing normally at 5 years of age. CONCLUSION: Although the natural history of isobutyryl-CoA dehydrogenase deficiency must be further defined, we have developed an algorithm for rapid laboratory evaluation of neonates with an isolated elevation of C4-acylcarnitine identified through newborn screening.

Original languageEnglish (US)
Pages (from-to)108-116
Number of pages9
JournalGenetics in Medicine
Volume9
Issue number2
DOIs
StatePublished - Feb 2007

Fingerprint

Newborn Infant
Butyryl-CoA Dehydrogenase
Urine
Isobutyryl-CoA dehydrogenase deficiency
acylcarnitine
Carnitine
Lost to Follow-Up
Valine
Missense Mutation
Natural History
Cardiomyopathies
Dehydration
Vomiting
2-methylacyl-CoA dehydrogenase
Anemia
Molecular Biology
Hospitalization
Fibroblasts
Biomarkers
Acids

Keywords

  • ACAD8
  • Acylcarnitine analysis
  • Isobutyryl-CoA dehydrogenase deficiency
  • Newborn screening
  • Tandem mass spectrometry

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics

Cite this

Development of a newborn screening follow-up algorithm for the diagnosis of isobutyryl-CoA dehydrogenase deficiency. / Oglesbee, Devin; He, Miao; Majumder, Nilanjana; Vockley, Jerry; Ahmad, Ayesha; Angle, Brad; Burton, Barbara; Charrow, Joel; Ensenauer, Regina; Ficicioglu, Can H.; Keppen, Laura Davis; Marsden, Deborah; Tortorelli, Silvia; Hahn, Si Houn; Matern, Dietrich.

In: Genetics in Medicine, Vol. 9, No. 2, 02.2007, p. 108-116.

Research output: Contribution to journalArticle

Oglesbee, D, He, M, Majumder, N, Vockley, J, Ahmad, A, Angle, B, Burton, B, Charrow, J, Ensenauer, R, Ficicioglu, CH, Keppen, LD, Marsden, D, Tortorelli, S, Hahn, SH & Matern, D 2007, 'Development of a newborn screening follow-up algorithm for the diagnosis of isobutyryl-CoA dehydrogenase deficiency', Genetics in Medicine, vol. 9, no. 2, pp. 108-116. https://doi.org/10.1097/GIM.0b013e31802f78d6
Oglesbee, Devin ; He, Miao ; Majumder, Nilanjana ; Vockley, Jerry ; Ahmad, Ayesha ; Angle, Brad ; Burton, Barbara ; Charrow, Joel ; Ensenauer, Regina ; Ficicioglu, Can H. ; Keppen, Laura Davis ; Marsden, Deborah ; Tortorelli, Silvia ; Hahn, Si Houn ; Matern, Dietrich. / Development of a newborn screening follow-up algorithm for the diagnosis of isobutyryl-CoA dehydrogenase deficiency. In: Genetics in Medicine. 2007 ; Vol. 9, No. 2. pp. 108-116.
@article{46812cbf639c4e878d832cb63fbdeade,
title = "Development of a newborn screening follow-up algorithm for the diagnosis of isobutyryl-CoA dehydrogenase deficiency",
abstract = "PURPOSE: Isobutyryl-CoA dehydrogenase deficiency is a defect in valine metabolism and was first reported in a child with cardiomyopathy, anemia, and secondary carnitine deficiency. We identified 13 isobutyryl-CoA dehydrogenase-deficient patients through newborn screening due to an elevation of C4-acylcarnitine in dried blood spots. Because C4-acylcarnitine represents both isobutyryl- and butyrylcarnitine, elevations are not specific for isobutyryl-CoA dehydrogenase deficiency but are also observed in short-chain acyl-CoA dehydrogenase deficiency. To delineate the correct diagnosis, we have developed a follow-up algorithm for abnormal C4-acylcarnitine newborn screening results based on the comparison of biomarkers for both conditions. METHODS: Fibroblast cultures were established from infants with C4-acylcarnitine elevations, and the analysis of in vitro acylcarnitine profiles provided confirmation of either isobutyryl-CoA dehydrogenase or short-chain acyl-CoA dehydrogenase deficiency. Isobutyryl-CoA dehydrogenase deficiency was further confirmed by molecular genetic analysis of the gene encoding isobutyryl-CoA dehydrogenase (ACAD8). Plasma acylcarnitines, urine acylglycines, organic acids, and urine acylcarnitine results were compared between isobutyryl-CoA dehydrogenase- and short-chain acyl-CoA dehydrogenase-deficient patients. RESULTS: Quantification of C4-acylcarnitine in plasma and urine as well as ethylmalonic acid in urine allows the differentiation of isobutyryl-CoA dehydrogenase-deficient from short-chain acyl-CoA dehydrogenase-deficient cases. In nine unrelated patients with isobutyryl-CoA dehydrogenase deficiency, 10 missense mutations were identified in ACAD8. To date, 10 of the 13 isobutyryl-CoA dehydrogenase-deficient patients remain asymptomatic, two were lost to follow-up, and one patient required frequent hospitalizations due to emesis and dehydration but is developing normally at 5 years of age. CONCLUSION: Although the natural history of isobutyryl-CoA dehydrogenase deficiency must be further defined, we have developed an algorithm for rapid laboratory evaluation of neonates with an isolated elevation of C4-acylcarnitine identified through newborn screening.",
keywords = "ACAD8, Acylcarnitine analysis, Isobutyryl-CoA dehydrogenase deficiency, Newborn screening, Tandem mass spectrometry",
author = "Devin Oglesbee and Miao He and Nilanjana Majumder and Jerry Vockley and Ayesha Ahmad and Brad Angle and Barbara Burton and Joel Charrow and Regina Ensenauer and Ficicioglu, {Can H.} and Keppen, {Laura Davis} and Deborah Marsden and Silvia Tortorelli and Hahn, {Si Houn} and Dietrich Matern",
year = "2007",
month = "2",
doi = "10.1097/GIM.0b013e31802f78d6",
language = "English (US)",
volume = "9",
pages = "108--116",
journal = "Genetics in Medicine",
issn = "1098-3600",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Development of a newborn screening follow-up algorithm for the diagnosis of isobutyryl-CoA dehydrogenase deficiency

AU - Oglesbee, Devin

AU - He, Miao

AU - Majumder, Nilanjana

AU - Vockley, Jerry

AU - Ahmad, Ayesha

AU - Angle, Brad

AU - Burton, Barbara

AU - Charrow, Joel

AU - Ensenauer, Regina

AU - Ficicioglu, Can H.

AU - Keppen, Laura Davis

AU - Marsden, Deborah

AU - Tortorelli, Silvia

AU - Hahn, Si Houn

AU - Matern, Dietrich

PY - 2007/2

Y1 - 2007/2

N2 - PURPOSE: Isobutyryl-CoA dehydrogenase deficiency is a defect in valine metabolism and was first reported in a child with cardiomyopathy, anemia, and secondary carnitine deficiency. We identified 13 isobutyryl-CoA dehydrogenase-deficient patients through newborn screening due to an elevation of C4-acylcarnitine in dried blood spots. Because C4-acylcarnitine represents both isobutyryl- and butyrylcarnitine, elevations are not specific for isobutyryl-CoA dehydrogenase deficiency but are also observed in short-chain acyl-CoA dehydrogenase deficiency. To delineate the correct diagnosis, we have developed a follow-up algorithm for abnormal C4-acylcarnitine newborn screening results based on the comparison of biomarkers for both conditions. METHODS: Fibroblast cultures were established from infants with C4-acylcarnitine elevations, and the analysis of in vitro acylcarnitine profiles provided confirmation of either isobutyryl-CoA dehydrogenase or short-chain acyl-CoA dehydrogenase deficiency. Isobutyryl-CoA dehydrogenase deficiency was further confirmed by molecular genetic analysis of the gene encoding isobutyryl-CoA dehydrogenase (ACAD8). Plasma acylcarnitines, urine acylglycines, organic acids, and urine acylcarnitine results were compared between isobutyryl-CoA dehydrogenase- and short-chain acyl-CoA dehydrogenase-deficient patients. RESULTS: Quantification of C4-acylcarnitine in plasma and urine as well as ethylmalonic acid in urine allows the differentiation of isobutyryl-CoA dehydrogenase-deficient from short-chain acyl-CoA dehydrogenase-deficient cases. In nine unrelated patients with isobutyryl-CoA dehydrogenase deficiency, 10 missense mutations were identified in ACAD8. To date, 10 of the 13 isobutyryl-CoA dehydrogenase-deficient patients remain asymptomatic, two were lost to follow-up, and one patient required frequent hospitalizations due to emesis and dehydration but is developing normally at 5 years of age. CONCLUSION: Although the natural history of isobutyryl-CoA dehydrogenase deficiency must be further defined, we have developed an algorithm for rapid laboratory evaluation of neonates with an isolated elevation of C4-acylcarnitine identified through newborn screening.

AB - PURPOSE: Isobutyryl-CoA dehydrogenase deficiency is a defect in valine metabolism and was first reported in a child with cardiomyopathy, anemia, and secondary carnitine deficiency. We identified 13 isobutyryl-CoA dehydrogenase-deficient patients through newborn screening due to an elevation of C4-acylcarnitine in dried blood spots. Because C4-acylcarnitine represents both isobutyryl- and butyrylcarnitine, elevations are not specific for isobutyryl-CoA dehydrogenase deficiency but are also observed in short-chain acyl-CoA dehydrogenase deficiency. To delineate the correct diagnosis, we have developed a follow-up algorithm for abnormal C4-acylcarnitine newborn screening results based on the comparison of biomarkers for both conditions. METHODS: Fibroblast cultures were established from infants with C4-acylcarnitine elevations, and the analysis of in vitro acylcarnitine profiles provided confirmation of either isobutyryl-CoA dehydrogenase or short-chain acyl-CoA dehydrogenase deficiency. Isobutyryl-CoA dehydrogenase deficiency was further confirmed by molecular genetic analysis of the gene encoding isobutyryl-CoA dehydrogenase (ACAD8). Plasma acylcarnitines, urine acylglycines, organic acids, and urine acylcarnitine results were compared between isobutyryl-CoA dehydrogenase- and short-chain acyl-CoA dehydrogenase-deficient patients. RESULTS: Quantification of C4-acylcarnitine in plasma and urine as well as ethylmalonic acid in urine allows the differentiation of isobutyryl-CoA dehydrogenase-deficient from short-chain acyl-CoA dehydrogenase-deficient cases. In nine unrelated patients with isobutyryl-CoA dehydrogenase deficiency, 10 missense mutations were identified in ACAD8. To date, 10 of the 13 isobutyryl-CoA dehydrogenase-deficient patients remain asymptomatic, two were lost to follow-up, and one patient required frequent hospitalizations due to emesis and dehydration but is developing normally at 5 years of age. CONCLUSION: Although the natural history of isobutyryl-CoA dehydrogenase deficiency must be further defined, we have developed an algorithm for rapid laboratory evaluation of neonates with an isolated elevation of C4-acylcarnitine identified through newborn screening.

KW - ACAD8

KW - Acylcarnitine analysis

KW - Isobutyryl-CoA dehydrogenase deficiency

KW - Newborn screening

KW - Tandem mass spectrometry

UR - http://www.scopus.com/inward/record.url?scp=33847081531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847081531&partnerID=8YFLogxK

U2 - 10.1097/GIM.0b013e31802f78d6

DO - 10.1097/GIM.0b013e31802f78d6

M3 - Article

VL - 9

SP - 108

EP - 116

JO - Genetics in Medicine

JF - Genetics in Medicine

SN - 1098-3600

IS - 2

ER -